B- and T-cell-specific inactivation of thioredoxin reductase 2 does not impair lymphocyte development and maintenance

Biological Chemistry

Volumn 388, Issue 10, 2007, Pages 1083-1090

  Geisberger, Roland ^a,b   Kiermayer, Claudia ^a   Hömig, Cornelia ^a,c   Conrad, Marcus ^a   Schmidt, Jörg ^a   Zimber Strobl, Ursula ^a   Brielmeier, Markus ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

CD19 Cre; CD4 Cre; Conditional knockout; Lymphocyte; Selenoprotein

Indexed keywords

CD19 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; INTERLEUKIN 4; THIOREDOXIN REDUCTASE; THIOREDOXIN REDUCTASE 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; ENZYME DEFICIENCY; ENZYME INACTIVATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; THYMUS; TRANSGENIC MOUSE;

ANIMALS; B-LYMPHOCYTES; CELL DIFFERENTIATION; FEMALE; FLOW CYTOMETRY; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, TRANSGENIC; PRECURSOR CELLS, B-LYMPHOID; PRECURSOR CELLS, T-LYMPHOID; T-LYMPHOCYTES; THIOREDOXIN REDUCTASE 2;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 35348817982     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2007.131     Document Type: Article

References (30)

1. Arner, E.S. and Holmgren, A. (2000). Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267, 6102-6109.
2. Beckett, G.J. and Arthur, J.R. (2005). Selenium and endocrine systems. J. Endocrinol. 184, 455-465.
3. Bertini, R., Howard, O.M., Dong, H.F., Oppenheim, J.J., Bizzarri, C., Sergi, R., Caselli, G., Pagliei, S., Romines, B., Wilshire, J.A., et al. (1999). Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J. Exp. Med. 189, 1783-1789.
4. Conrad, M., Jakupoglu, C., Moreno, S.G., Lippl, S., Banjac, A., Schneider, M., Beck, H., Hatzopoulos, A.K., Just, U., Sinowatz, F., et al. (2004). Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol. Cell. Biol. 24, 9414-9423.
5. Ericson, M.L., Horling, J., Wendel-Hansen, V., Holmgren, A., and Rosen, A. (1992). Secretion of thioredoxin after in vitro activation of human B cells. Lymphokine Cytokine Res. 11, 201-207.
6. Gasdaska, P.Y., Gasdaska, J.R., Cochran, S., and Powis, G. (1995). Cloning and sequencing of a human thioredoxin reductase. FEBS Lett. 373, 5-9.
7. Gasdaska, P.Y., Berggren, M.M., Berry, M.J., and Powis, G. (1999). Cloning, sequencing and functional expression of a novel human thioredoxin reductase. FEBS Lett. 442, 105-111.
8. Gladyshev, V.N., Jeang, K.T., and Stadtman, T.C. (1996). Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc. Natl. Acad. Sci. USA 93, 6146-6151.
9. Iwata, S., Hori, T., Sato, N., Hirota, K., Sasada, T., Mitsui, A., Hirakawa, T., and Yodoi, J. (1997). Adult T cell leukemia (ATL)-derived factor/human thioredoxin prevents apoptosis of lymphoid cells induced by L-cystine and glutathione depletion: possible involvement of thiol-mediated redox regulation in apoptosis caused by pro-oxidant state. J. Immunol. 158, 3108-3117.
10. Jakupoglu, C., Przemeck, G.K., Schneider, M., Moreno, S.G., Mayr, N., Hatzopoulos, A.K., de Angelis, M.H., Wurst, W., Bornkamm, G.W., Brielmeier, M., et al. (2005). Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for cardiac development. Mol. Cell. Biol. 25, 1980-1988.
11. Karimpour, S., Lou, J., Lin, L.L., Rene, L.M., Lagunas, L., Ma, X., Karra, S., Bradbury, C.M., Markovina, S., Goswami, P.C., et al. (2002). Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation. Oncogene 21, 6317-6327.
12. Kryukov, G.V., Castellano, S., Novoselov, S.V., Lobanov, A.V., Zehtab, O., Guigo, R., and Gladyshev, V.N. (2003). Characterization of mammalian selenoproteomes. Science 300, 1439-1443.
13. Li, L., Shoji, W., Takano, H., Nishimura, N., Aoki, Y., Takahashi, R., Goto, S., Kaifu, T., Takai, T., and Obinata, M. (2007). Increased susceptibility of MER5 (peroxiredoxin III) knockout mice to LPS-induced oxidative stress. Biochem. Biophys. Res. Commun. 355, 715-721.
14. Lillig, C.H. and Holmgren, A. (2007). Thioredoxin and related molecules - from biology to health and disease. Antioxid. Redox Signal. 9, 25-47.
15. Matsui, M., Oshima, M., Oshima, H., Takaku, K., Maruyama, T., Yodoi, J., and Taketo, M.M. (1996). Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev. Biol. 178, 179-185.
16. McKenzie, R.C., Rafferty, T.S., and Beckett, G.J. (1998). Selenium: an essential element for immune function. Immunol. Today 19, 342-345.
17. Moon, E.Y., Noh, Y.W., Han, Y.H., Kim, S.U., Kim, J.M., Yu, D.Y., and Lim, J.S. (2006). T lymphocytes and dendritic cells are activated by the deletion of peroxiredoxin II (Prx II) gene. Immunol. Lett. 102, 184-190.
18. Nagy, N., Malik, G., Fisher, A.B., and Das, D.K. (2006). Targeted disruption of peroxiredoxin 6 gene renders the heart vulnerable to ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 291, H2636-H2640.
19. Nishinaka, Y., Nakamura, H., and Yodoi, J. (2002). Thioredoxin cytokine action. Methods Enzymol. 347, 332-338.
20. Nonn, L., Williams, R.R., Erickson, R.P., and Powis, G. (2003). The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol. Cell. Biol. 23, 916-922.
21. Patrick, L. (2004). Selenium biochemistry and cancer: a review of the literature. Altern. Med. Rev. 9, 239-258.
22. Qin, J., Clore, G.M., Kennedy, W.M., Huth, J.R., and Gronenborn, A.M. (1995). Solution structure of human thioredoxin in a mixed disulfide intermediate complex with its target peptide from the transcription factor NF-κB. Structure 3, 289-297.
23. Rickert, R.C., Roes, J., and Rajewsky, K. (1997). B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res. 25, 1317-1318.
24. Sun, Q.A., Kirnarsky, L., Sherman, S., and Gladyshev, V.N. (2001). Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems. Proc. Natl. Acad. Sci. USA 98, 3673-3678.
25. Tagaya, Y., Maeda, Y., Mitsui, A., Kondo, N., Matsui, H., Hamuro, J., Brown, N., Arai, K., Yokota, T., Wakasugi, H., et al. (1989). ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J. 8, 757-764.
26. Teshigawara, K., Maeda, M., Nishino, K., Nikaido, T., Uchiyama, T., Tsudo, M., Wano, Y., and Yodoi, J. (1985). Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression. J. Mol. Cell. Immunol. 2, 17-26.
27. Wakasugi, N., Tagaya, Y., Wakasugi, H., Mitsui, A., Maeda, M., Yodoi, J., and Tursz, T. (1990). Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc. Natl. Acad. Sci. USA 87, 8282-8286.
28. Wolfer, A., Bakker, T., Wilson, A., Nicolas, M., Ioannidis, V., Littman, D.R., Lee, P.P., Wilson, C.B., Held, W., MacDonald, H.R., et al. (2001). Inactivation of Notch 1 in immature thymocytes does not perturb CD4 or CD8T cell development. Nat. Immunol. 2, 235-241.
29. Wolfer, A., Wilson, A., Nemir, M., MacDonald, H.R., and Radtke, F. (2002). Inactivation of Notch1 impairs VDJbeta rearrangement and allows pre-TCR-independent survival of early αβ lineage thymocytes. Immunity 16, 869-879.
30. Wood, Z.A., Poole, L.B., and Karplus, P.A. (2003). Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science 300, 650-653.